MWNA
NTGN

Marshall Wace North America’s Neon Therapeutics, Inc. Common Stock NTGN Stock Holding History

Marshall Wace North America’s Portfolio NTGN Stock Details NTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-7,549
Closed -$49K – 1839
2019
Q1 		$49K Buy
+7,549
New +$39.5K ﹤0.01% 1268
2018
Q3 		– Sell
-42,100
Closed -$530K – 1570
2018
Q2 		$530K Buy
+42,100
New +$576K ﹤0.01% 1071

Other funds holding NTGN

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return

Marshall Wace North America's NTGN Position: Q2 2019 in Review

Marshall Wace North America sold out of Neon Therapeutics, Inc. Common Stock (NTGN) in Q2 2019, closing a stake of 7,549 shares — an estimated $49K sold.

Marshall Wace North America first reported a position in NTGN in Q2 2018 and held it in 2 quarters. The position peaked at $530K in Q2 2018. 51 funds tracked by Wall St. Rank hold NTGN as of Q2 2019.

  • Marshall Wace North America reported no remaining Neon Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Marshall Wace North America sold 7,549 Neon Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $49K.
  • Marshall Wace North America first reported a position in Neon Therapeutics, Inc. Common Stock in Q2 2018 and held it in 2 quarters.
  • Marshall Wace North America's Neon Therapeutics, Inc. Common Stock position peaked at $530K in Q2 2018.
  • 51 funds tracked by Wall St. Rank held Neon Therapeutics, Inc. Common Stock as of Q2 2019.

Based on Marshall Wace North America's 13F filing for Q2 2019, filed 14 Aug 2019.